• 4-(Aminomethyl)benzoic Acid (PAMBA),YCHEMIR,4-(Aminomethyl)benzoic Acid (PAMBA)
  • 4-(Aminomethyl)benzoic Acid (PAMBA),YCHEMIR,4-(Aminomethyl)benzoic Acid (PAMBA)

4-(Aminomethyl)benzoic Acid (PAMBA)

No.56-91-7

4-(Aminomethyl)benzoic Acid (PAMBA, CAS 56-91-7) is high‑purity white crystalline antifibrinolytic pharmaceutical API, widely used as haemostatic drug raw‑material and pharmaceutical‑impurity reference‑standard for laboratory‑analysis and pharmacology research.

Download
View all downloads
  • 4-(Aminomethyl)benzoic Acid (PAMBA),YCHEMIR,4-(Aminomethyl)benzoic Acid (PAMBA)

Description

Chemical Name: 4-(Aminomethyl)benzoic Acid (PAMBA)

Synonyms: PAMBA, p-Aminomethylbenzoic Acid, Aminomethylbenzoic Acid, Para-aminomethylbenzoic acid, Tranexamic Acid EP Impurity D

CAS NO: 56-91-7

EINECS Number: 200‑297‑9

Formula: C₈H₉NO₂

Molecular Weight: 151.16 g/mol

Product Type: Antifibrinolytic pharmaceutical API, haemostatic raw‑material, pharmacology research reagent, pharmaceutical reference standard

Item

Specification

Appearance

White to off‑white flaky crystalline powder

Purity

≥98.0 %

Loss on Drying

≤0.5 %

Melting Point

>300 ℃

Density (25 ℃, g/cm3)

1.20‑1.24 g/cm³

Flash Point

149.2 ℃

Description:

4-(Aminomethyl)benzoic Acid (PAMBA, CAS 56-91-7) is a synthetic lysine‑analogue antifibrinolytic compound, presented as white‑to‑off‑white odourless flaky crystalline powder under ambient conditions. It competitively occupies lysine‑binding sites on plasminogen, inhibits conversion of plasminogen to plasmin, prevents fibrin degradation and exerts haemostatic effect. Its antifibrinolytic potency is stronger than aminocaproic acid.

This substance shows slight solubility in cold water and dissolves better in boiling water. It dissolves in dilute alkali solution to form corresponding salt. Qualified batches contain no harmful heavy‑metal impurities, suitable for pharmaceutical raw‑material production, pharmacology study and pharmacopoeia reference‑standard preparation.

Core advantages: Potent antifibrinolytic‑haemostatic activity, good thermal stability under dry condition, well‑documented pharmacological data, compliant with pharmaceutical‑API quality requirements.

Application:

  • Pharmaceutical Industry: Antifibrinolytic active pharmaceutical ingredient for oral solid preparations and injection formulations; applied for prevention and treatment of haemorrhage caused by systemic or local fibrinolysis, especially for chronic oozing bleeding.
  • Pharmaceutical‑Reference Material: EP reference standard (Tranexamic Acid Impurity D) used for related‑substance testing of tranexamic acid drug substances and finished dosage forms.
  • Biochemical & Laboratory Research: Standard reagent for fibrinolysis‑pathway, haematology and pharmacology mechanism research.
  • Fine‑Chemical Synthesis: Building‑block intermediate for amino‑benzene‑derivative synthesis.

Packaging: Lab scale: sealed amber glass bottle / aluminum‑foil bag (10 g / 50 g /100 g /500 g); bulk: 1 kg /5 kg /25 kg sealed moisture‑proof composite plastic drum. Custom packaging available upon request.

Storage: Store in cool, dry, dust‑free warehouse with low relative‑humidity. Keep containers tightly sealed against moisture. Recommended storage temperature: 5‑25 ℃; for reference‑standard grade, store at 2‑8 ℃. Keep away from heat sources and strong oxidizing agents. Inert‑gas sealed storage is preferred for long‑term preservation.

Shelf Life: 24 months for unopened original sealed packages under standard storage conditions. Immediately reseal after opening and consume within 3 months to assure purity and stability.